Marksans Pharma Ltd. Share Price

Marksans Pharma Ltd has posted a strong Q1 FY27 performance

Marksans Pharma Ltd has posted a strong Q1 FY27 performance, driven by robust exports and steady domestic growth. The company’s consolidated revenue rose 22.4 % year‑on‑year to ₹ 706.5 crore, while net profit jumped 31.8 % to ₹ 118.2 crore. 💊 Q1 FY27 Financial Highlights Metric Q1 FY27 Q1 FY26 Growth YoY Revenue from Operations ₹ 706.5 crore ₹ 577.3 crore + 22.4 % EBITDA ₹ 157.8 crore ₹ 122.6 crore + 28.7 % EBITDA Margin 22.3 % 21.2 % + 1.1 pp PAT ₹ 118.2 crore ₹ 89.7 crore + 31.8 % EPS (Diluted) ₹ 2.85 ₹ 2.17 + 31.3 % Key drivers: Strong performance in regulated markets (US, UK, Australia). Growth in OTC and prescription segments. Operational efficiency from ABCnow GmbH acquisition and integration synergies. 🏭 Strategic Updates ABCnow GmbH integration completed; expected to add ₹ 250 crore annual revenue. New product launches in pain management and gastro segments. Capex plan of ₹ 150 crore for expansion of Goa and UK facilities. Focus on Europe and US growth through new ANDA filings and partnerships. 💹 Stock Performance (14 Aug 2026) Exchange Price Change Trend BSE ₹ 189.40 ▲ + 4.25 % Bullish short‑term NSE ₹ 188.85 ▲ + 4.10 % Positive momentum 52‑week range: ₹ 132.50 – ₹ 192.00 Technical outlook: Consolidation near ₹ 190 resistance; breakout could target ₹ 210 levels. ⚠️ Risks & Investor Watchpoints Regulatory compliance in EU and US markets. Currency fluctuations impacting export margins. Integration risks from recent acquisitions. In summary: Marksans Pharma Ltd continues its upward trajectory with strong export‑led growth and successful integration of ABCnow GmbH. The company’s focus on regulated markets and new product launches positions it well for sustained profitability.

See More

Update for investors of Marksans

is currently trading at Rs. 316.05, up by 37.15 points or 13.32% from its previous closing of Rs. 278.90 on the BSE. The scrip opened at Rs. 280.40 and has touched a high and low of Rs. 319.90 and Rs. 277.30 respectively. So far 1446137 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 319.90 on 12-Aug-2026 and a 52 week low of Rs. 156.00 on 30-Mar-2026. Last one week high and low of the scrip stood at Rs. 319.90 and Rs. 266.80 respectively. The current market cap of the company is Rs. 14238.40 crore. The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 23.66% and 32.47% respectively. Marksans Pharma has reported 43.65% jump in its net profit at Rs 69.04 crore for the first quarter ended June 30, 2026 (Q1FY27) as compared to Rs 48.06 crore for the same quarter in the previous year. The total income of the company has increased by 5.26% at Rs 338.66 crore for Q1FY27 as compared to Rs 321.74 crore for the corresponding quarter previous year. On consolidated basis, the company has reported near three-fold jump in its net profit at Rs 157.17 crore for Q1FY27 as compared to Rs 58.32 crore for the same quarter in the previous year. The total income of the company has increased by 38.45% at Rs 866.20 crore for Q1FY27 as compared to Rs 625.63 crore for the corresponding quarter previous year.

See More

Marksans Pharma Ltd – Company Analysis

Marksans Pharma Ltd is a growing pharmaceutical company focused on developing, manufacturing and marketing generic and over-the-counter (OTC) medicines, with a strong presence in regulated markets such as the US, UK, Australia and Canada. The company has built a sizeable portfolio across pain management, cough and cold, gastrointestinal, vitamins and other healthcare categories, while expanding its manufacturing capacity and product pipeline. Financial performance has been strong, with FY26 operating revenue rising 12.5% to approximately ₹2,951 crore and EBITDA increasing 12.8% to ₹601 crore. Q4 FY26 was particularly impressive, with operating revenue growing 20.8% year-on-year to ₹856 crore, while EBITDA jumped 54% to ₹195 crore and EBITDA margin expanded to 22.8%. Net profit for the quarter was ₹149 crore, up 64% year-on-year, highlighting significant operating leverage and improving profitability. Over the last three years, revenue has grown at around 21% CAGR and profit at approximately 27% CAGR. The latest Q1 FY27 result has further strengthened the investment case, with profit after tax reportedly surging 174% year-on-year to ₹159 crore. Going forward, Marksans can benefit from new product launches, expansion in regulated markets, increased manufacturing capacity and continued growth in the global OTC and generic pharmaceutical markets. However, investors should monitor regulatory approvals, USFDA compliance, pricing pressure in international markets, currency movements and acquisition-related execution risks. Overall, Marksans Pharma has developed into a high-growth, profitable pharmaceutical company with improving margins, strong earnings momentum and a relatively reasonable valuation. The key question is whether the exceptional recent profit growth can be sustained rather than being treated as a one-off spike.

See More

Marksans Pharma posted Strong Q1 FY27 Performance

shares reported a sharp improvement in Q1 FY27 profitability, with strong growth across its international formulation businesses. Key Financial Highlights PAT: ₹159 crore, up 174% YoY Operating Revenue: ₹841 crore, up 35.6% YoY EBITDA: ₹213 crore, up 113% YoY Cash Balance: ₹1,058 crore, crossing the ₹1,000 crore mark for the first time. What Drove the Growth? The biggest positive was the company's UK & Europe formulation business, which reported its highest-ever quarterly revenue of ₹356 crore, growing 74.7% YoY. New product launches and continued market-share gains supported the performance. The US & North America formulation business, which is the company's largest market, generated ₹377 crore in revenue, up 15.1% YoY. Australia and New Zealand also delivered strong growth, with revenue rising 53.7% to ₹88 crore. The company also completed the acquisition of QliniQ in the Netherlands and ABCnow GmbH in Germany during the quarter. QliniQ contributed ₹44 crore of revenue in Q1, marking the beginning of Marksans' European expansion strategy.

See More

Marksans Pharma shares jumped over 11% today

Marksans Pharma shares jumped over 11% today after reporting stellar Q1 FY27 results — profit nearly tripled to ₹157 crore, revenue rose 36% YoY, and EBITDA margin expanded sharply to 25.3%. The company also crossed ₹1,000 crore in cash reserves and strengthened its European presence through acquisitions of QliniQ B.V. (Netherlands) and ABCnow GmbH (Germany). 💰 Q1 FY27 Financial Highlights Metric Q1 FY27 Q1 FY26 YoY Change Revenue from Operations ₹ 840.8 crore ₹ 620 crore +35.6 % EBITDA ₹ 213 crore ₹ 100 crore +112.8 % EBITDA Margin 25.3 % 16.2 % +910 bps PAT (Consolidated) ₹ 157.17 crore ₹ 58.32 crore +169.5 % Cash Balance ₹ 1,058 crore — Record High 🌍 Regional Performance UK & Europe: ₹ 356 crore revenue (+74.7 % YoY) — highest ever; driven by new product launches and market share gains. US & North America: ₹ 377 crore revenue (+15.1 % YoY) — 45 % of total sales; strong order pipeline. Australia & New Zealand: ₹ 88 crore revenue (+53.7 % YoY) — portfolio expansion and new launches. Rest of World: ₹ 20 crore revenue (–36.8 % YoY) — impacted by Middle East shipment delays but sequential improvement. 🧩 Strategic Moves & Acquisitions QliniQ B.V. (Netherlands): Acquired 100 % stake for € 7.5 million. ABCnow GmbH (Germany): Definitive agreement for € 1.1 million purchase. These deals expand Marksans’ footprint in regulated European markets and enhance its product distribution network. 📈 Market Reaction Share Price: Up 11–13 % intraday; trading near ₹ 190 levels. Volume Spike: Heavy delivery buying after results announcement. Analyst Sentiment: Angel One: “Strong profitability and cash position support long‑term growth.” CNBC TV18: “Record EBITDA and margin expansion signal robust execution.” 🔮 Outlook & Risks Positive Drivers Sustained growth in regulated markets (UK, US, EU). Integration of QliniQ and ABCnow to boost European revenues. Strong cash reserves → capacity for organic and inorganic expansion.

See More

Profitability at all-time highs - Marksans Pharma Ltd

Code BSE: 524404 NSE:

Marksans Pharma delivers record Q1FY27 — Profitability at all-time highs, cash crosses Rs 1,000 crore Q1FY27 Financial Highlights a) Operating Revenue stood at Rs. 841 cr., up by 35.6% YoY b) Gross profit came in at Rs. 497 cr., up by 38.9% YoY, with a gross margin of 59.1% c) EBITDA stood at Rs. 213 cr., up by 112.8% YoY, with an EBITDA margin of 25.3% d) PAT stood at Rs. 159 cr., up by 173.9% YoY, with a net margin of 18.4% e) EPS was at Rs. 3.5

See More